Beta Bionics President and CEO Saint Sean sold 16,867 shares at $19.11 each on September 2, 2026. The transaction left him owning 404,070 Beta Bionics shares, giving investors the company-reported balance of his remaining shareholding after the sale.
Key Highlights
- Saint Sean completed the Beta Bionics share sale on September 2, 2026.
- Saint Sean is Beta Bionics’ President and CEO.
- His reported ownership after the transaction was 404,070 shares.
Beta Bionics, Inc. (NASDAQ: BBNX) shares sold by President and CEO Saint Sean totaled 16,867 at $19.11 per share. The transaction took place on September 2, 2026, and left Saint Sean with 404,070 shares.
Saint Sean’s Remaining Beta Bionics Holdings
Saint Sean’s transaction involved shares of Beta Bionics, Inc. the company identified in the regulatory disclosure. His position following the sale was reported at 404,070 shares. Saint Sean holds the titles of President and CEO at Beta Bionics. The reported sale price was $19.11 for each of the 16,867 shares sold. The transaction is dated September 2, 2026. The filing states that Saint Sean owned 404,070 shares following the transaction.
FAQs
Q: How many Beta Bionics shares did Saint Sean sell?
A: According to the regulatory filing, Beta Bionics President and CEO Saint Sean sold 16,867 shares. The filing reported a transaction price of $19.11 per share.
Q: How many BBNX shares does Saint Sean own after the sale?
A: Saint Sean owned 404,070 Beta Bionics shares after the transaction. The reported holding reflects his position following the September 2, 2026 sale.
Q: When did the Beta Bionics CEO share sale occur?
A: The Beta Bionics CEO share sale occurred on September 2, 2026. Saint Sean sold 16,867 shares at $19.11 each on that date.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.